NCT02250807View on ClinicalTrials.gov

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Chronic Hepatitis CGenotype 4 Chronic Hepatitis C
Interventions
DRUG

Simeprevir

Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.

DRUG

Sofosbuvir

Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.

Trial Locations (6)

Unknown

Badalona

Barcelona

Madrid

Santander

Seville

Valencia

All Listed Sponsors
lead

Janssen R&D Ireland

INDUSTRY

NCT02250807 - Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection | Biotech Hunter | Biotech Hunter